Filter

Refine by collections

Refine by date

—
  • Print
  • Save

Search Results

You are looking at 1 - 10 of 21 items for :

Clear All
Kosmas Daskalakis Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
1st Department of Propaupaedic Internal Medicine, Endocrine Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Kosmas Daskalakis in
Google Scholar
PubMed Close
,
Marina Tsoli 1st Department of Propaupaedic Internal Medicine, Endocrine Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Marina Tsoli in
Google Scholar
PubMed Close
,
Anna Angelousi 1st Department of Propaupaedic Internal Medicine, Endocrine Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Anna Angelousi in
Google Scholar
PubMed Close
,
Evanthia Kassi 1st Department of Propaupaedic Internal Medicine, Endocrine Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Evanthia Kassi in
Google Scholar
PubMed Close
,
Krystallenia I Alexandraki 1st Department of Propaupaedic Internal Medicine, Endocrine Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Krystallenia I Alexandraki in
Google Scholar
PubMed Close
,
Denise Kolomodi 1st Department of Propaupaedic Internal Medicine, Endocrine Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Denise Kolomodi in
Google Scholar
PubMed Close
,
Gregory Kaltsas 1st Department of Propaupaedic Internal Medicine, Endocrine Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece
Clinical Sciences Research Laboratories, Warwick Medical School, University of Warwick, University Hospital, Coventry, UK
Centre of Applied Biological & Exercise Sciences, Faculty of Health & Life Sciences, Coventry University, Coventry, UK

Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed Close
, and
Anna Koumarianou Haematology-Oncology Unit, Fourth Department of Internal Medicine, Attikon University General Hospital, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Anna Koumarianou in
Google Scholar
PubMed Close

). MTTs with the MTOR inhibitor everolimus and the receptor tyrosine kinase (RTK) inhibitor sunitinib have been approved in clinical practice for locally advanced and metastatic pancreatic NENs (PanNENs) ( 2 , 3 ). In addition, everolimus has been shown

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-19-0134
Volume/Issue:
Volume 8: Issue 6
Open access
Giulia Bresciani Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy

Search for other papers by Giulia Bresciani in
Google Scholar
PubMed Close
,
Angeliki Ditsiou Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK

Search for other papers by Angeliki Ditsiou in
Google Scholar
PubMed Close
,
Chiara Cilibrasi Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK

Search for other papers by Chiara Cilibrasi in
Google Scholar
PubMed Close
,
Viviana Vella Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK

Search for other papers by Viviana Vella in
Google Scholar
PubMed Close
,
Federico Rea Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy

Search for other papers by Federico Rea in
Google Scholar
PubMed Close
,
Marco Schiavon Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy

Search for other papers by Marco Schiavon in
Google Scholar
PubMed Close
,
Narciso Giorgio Cavallesco Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy

Search for other papers by Narciso Giorgio Cavallesco in
Google Scholar
PubMed Close
,
Georgios Giamas Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK

Search for other papers by Georgios Giamas in
Google Scholar
PubMed Close
,
Maria Chiara Zatelli Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy

Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed Close
, and
Teresa Gagliano Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK

Search for other papers by Teresa Gagliano in
Google Scholar
PubMed Close

( 1 , 15 ). Everolimus and sunitinib are two targeted agents approved by the Food and Drugs Administration (FDA) for the treatment of different types of NENs ( 16 ). Everolimus is an mTOR inhibitor capable to slow down the tumour growth and arrest

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-19-0192
Volume/Issue:
Volume 8: Issue 6
Open access
Shan Wu College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, People’s Republic of China
Research Center for Translational Medicine, Cancer Stem Cell Institute, East Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

Search for other papers by Shan Wu in
Google Scholar
PubMed Close
,
Jianjun Zhou Research Center for Translational Medicine, Cancer Stem Cell Institute, East Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

Search for other papers by Jianjun Zhou in
Google Scholar
PubMed Close
,
Jing Guo Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, People’s Republic of China

Search for other papers by Jing Guo in
Google Scholar
PubMed Close
,
Zhan Hua Department of General Surgery, China-Japan Friendship Hospital, Beijing, People’s Republic of China

Search for other papers by Zhan Hua in
Google Scholar
PubMed Close
,
Jianchen Li College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, People’s Republic of China

Search for other papers by Jianchen Li in
Google Scholar
PubMed Close
, and
Zai Wang Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, People’s Republic of China

Search for other papers by Zai Wang in
Google Scholar
PubMed Close

), particularly in liver metastasis ( 10 ). For this reason, sunitinib, a multi-targeted tyrosine kinase receptor inhibitor of VEGFR1-3, platelet-derived growth factor receptor, mast/stem cell growth factor receptor kit, proto-oncogene tyrosine-protein kinase

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-18-0397
Volume/Issue:
Volume 8: Issue 1
Open access
E T Aristizabal Prada Department of Internal Medicine IV, Campus Grosshadern, University-Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany

Search for other papers by E T Aristizabal Prada in
Google Scholar
PubMed Close
and
C J Auernhammer Department of Internal Medicine IV, Campus Grosshadern, University-Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany

Search for other papers by C J Auernhammer in
Google Scholar
PubMed Close

disease of NETs of the GEP system ( 2 , 3 , 4 , 5 , 6 , 7 , 8 ), including molecular targeted therapy with the mammalian target of rapamycin (mTOR) inhibitor everolimus and the multi-tyrosinkinase inhibitor sunitinib, has significantly progressed

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-17-0286
Volume/Issue:
Volume 7: Issue 1
Open access
Anne Jouinot Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
Institut Cochin, INSERM U1016, CNRS UMR8104, Université Paris Descartes, Sorbonne Paris Cité, Paris, France

Search for other papers by Anne Jouinot in
Google Scholar
PubMed Close
,
Bernard Royer CHU Besançon, Clinical Pharmacology and Toxicology Dpt, Besançon cedex, France

Search for other papers by Bernard Royer in
Google Scholar
PubMed Close
,
Etienne Chatelut Institut Claudius-Regaud, Université de Toulouse, INSERM, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France

Search for other papers by Etienne Chatelut in
Google Scholar
PubMed Close
,
Sotheara Moeung Institut Claudius-Regaud, Université de Toulouse, INSERM, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France

Search for other papers by Sotheara Moeung in
Google Scholar
PubMed Close
,
Guillaume Assié Institut Cochin, INSERM U1016, CNRS UMR8104, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
Department of Endocrinology, Center for Rare Adrenal Diseases, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris, France

Search for other papers by Guillaume Assié in
Google Scholar
PubMed Close
,
Audrey Thomas-Schoemann Department of Pharmacy, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France

Search for other papers by Audrey Thomas-Schoemann in
Google Scholar
PubMed Close
,
Jérôme Bertherat Institut Cochin, INSERM U1016, CNRS UMR8104, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
Department of Endocrinology, Center for Rare Adrenal Diseases, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris, France

Search for other papers by Jérôme Bertherat in
Google Scholar
PubMed Close
,
François Goldwasser Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France

Search for other papers by François Goldwasser in
Google Scholar
PubMed Close
, and
Benoit Blanchet Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
UMR8638 CNRS, Pharmacy UFR, University of Paris Descartes, PRES sorbonne Paris Cité, Paris, France

Search for other papers by Benoit Blanchet in
Google Scholar
PubMed Close

, in a phase II trial, efficacy and toxicity of sunitinib (0% of response and 26% of grade 3–4 adverse events) were lower than expected in ACC patients. Most of these patients received mitotane and were underexposed to sunitinib compared to the target

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-18-0428
Volume/Issue:
Volume 7: Issue 12
Open access
Sondra O’Callaghan Endocrinology, Diabetes & Metabolism, Orlando VA Healthcare System, Orlando, Florida, USA

Search for other papers by Sondra O’Callaghan in
Google Scholar
PubMed Close
and
Hanford Yau Endocrinology, Diabetes & Metabolism, Orlando VA Healthcare System, Orlando, Florida, USA

Search for other papers by Hanford Yau in
Google Scholar
PubMed Close

.0–1.5 pmol/L or 0–14 ng/L). Tumor embolization failed, and funded sunitinib therapy was unavailable. Three weekly infusions of zolendronate and normal saline failed to control calcium and its symptoms, therefore cinacalcet was initiated and titrated. The

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-20-0487
Volume/Issue:
Volume 10: Issue 1
Open access
Kazhan Mollazadegan Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Search for other papers by Kazhan Mollazadegan in
Google Scholar
PubMed Close
,
Britt Skogseid Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Search for other papers by Britt Skogseid in
Google Scholar
PubMed Close
,
Johan Botling Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

Search for other papers by Johan Botling in
Google Scholar
PubMed Close
,
Tobias Åkerström Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

Search for other papers by Tobias Åkerström in
Google Scholar
PubMed Close
,
Barbro Eriksson Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Search for other papers by Barbro Eriksson in
Google Scholar
PubMed Close
,
Staffan Welin Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Search for other papers by Staffan Welin in
Google Scholar
PubMed Close
,
Anders Sundin Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

Search for other papers by Anders Sundin in
Google Scholar
PubMed Close
, and
Joakim Crona Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Search for other papers by Joakim Crona in
Google Scholar
PubMed Close

) or sunitinib ( n   = 5) ( 11 ). In addition, a median progression-free survival (PFS) of 4 months for peptide receptor radionuclide therapy (PRRT) has also been reported ( 12 ). Consequently, it has been hypothesized that panNET-G3 should be treated

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-21-0604
Volume/Issue:
Volume 11: Issue 3
Open access
Xu Han Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Xu Han in
Google Scholar
PubMed Close
,
Xuefeng Xu Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Xuefeng Xu in
Google Scholar
PubMed Close
,
Hongyun Ma Department of Pancreatic Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China

Search for other papers by Hongyun Ma in
Google Scholar
PubMed Close
,
Yuan Ji Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Yuan Ji in
Google Scholar
PubMed Close
,
Dansong Wang Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Dansong Wang in
Google Scholar
PubMed Close
,
Tiantao Kuang Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Tiantao Kuang in
Google Scholar
PubMed Close
,
Wenchuan Wu Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Wenchuan Wu in
Google Scholar
PubMed Close
,
Bin Song Department of Pancreatic Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China

Search for other papers by Bin Song in
Google Scholar
PubMed Close
,
Gang Li Department of Pancreatic Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China

Search for other papers by Gang Li in
Google Scholar
PubMed Close
,
Gang Jin Department of Pancreatic Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China

Search for other papers by Gang Jin in
Google Scholar
PubMed Close
, and
Wenhui Lou Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Wenhui Lou in
Google Scholar
PubMed Close

patients had received hepatic arterial chemoembolization (HACE), four patients had received radiofrequency ablation (RFA), five patients had received Octreotide LAR, three patients had received sunitinib, one patient had received everolimus, seven patients

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-17-0388
Volume/Issue:
Volume 7: Issue 2
Open access
Daniel Alexander Hescheler Department of Nuclear Medicine, University Hospital Münster, Münster, Germany
European Institute for Molecular Imaging (EIMI), University of Münster, Münster, Germany

Search for other papers by Daniel Alexander Hescheler in
Google Scholar
PubMed Close
,
Milan Janis Michael Hartmann Department of General, Visceral, Tumor and Transplant Surgery, University Hospital Cologne, Cologne, Germany

Search for other papers by Milan Janis Michael Hartmann in
Google Scholar
PubMed Close
,
Burkhard Riemann Department of Nuclear Medicine, University Hospital Münster, Münster, Germany

Search for other papers by Burkhard Riemann in
Google Scholar
PubMed Close
,
Maximilian Michel Institute of Zoology, University of Cologne Germany, Cologne, Germany

Search for other papers by Maximilian Michel in
Google Scholar
PubMed Close
,
Christiane Josephine Bruns Department of General, Visceral, Tumor and Transplant Surgery, University Hospital Cologne, Cologne, Germany

Search for other papers by Christiane Josephine Bruns in
Google Scholar
PubMed Close
,
Hakan Alakus Department of General, Visceral, Tumor and Transplant Surgery, University Hospital Cologne, Cologne, Germany

Search for other papers by Hakan Alakus in
Google Scholar
PubMed Close
, and
Costanza Chiapponi Department of General, Visceral, Tumor and Transplant Surgery, University Hospital Cologne, Cologne, Germany

Search for other papers by Costanza Chiapponi in
Google Scholar
PubMed Close

Retrospective, Spanish o_-label-sorafenib-use program DTC PR: 19% MTC PR: 47% ATC PR: 33% Hand–foot skin reaction, diarrhea, alopecia, skin rash or desquamation  Sunitinib  Ravaud et al. (26) VEGFR, PDGFR, RET, KIT, FLT DTC: 41 (RAI resistant

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-21-0624
Volume/Issue:
Volume 11: Issue 4
Open access
Hanbaro Kim Department of Surgery, Hallym University College of Medicine, Chuncheon, Republic of Korea

Search for other papers by Hanbaro Kim in
Google Scholar
PubMed Close
,
Ki Byung Song Division of Hepatobilliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea

Search for other papers by Ki Byung Song in
Google Scholar
PubMed Close
,
Dae Wook Hwang Division of Hepatobilliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea

Search for other papers by Dae Wook Hwang in
Google Scholar
PubMed Close
,
Jae Hoon Lee Division of Hepatobilliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea

Search for other papers by Jae Hoon Lee in
Google Scholar
PubMed Close
,
Shadi Alshammary Department of Surgery, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

Search for other papers by Shadi Alshammary in
Google Scholar
PubMed Close
, and
Song Cheol Kim Division of Hepatobilliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea

Search for other papers by Song Cheol Kim in
Google Scholar
PubMed Close

surgery. Adjuvant chemotherapy (including etoposide and cisplatin (EP) and capecitabine) and target therapy (including everolimus and sunitinib) were administered when recommended by oncologists. Follow-up Survival status was determined from

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-19-0282
Volume/Issue:
Volume 8: Issue 7
Open access